We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

February 11, 2022

A Round-up of 5 Expert Insights from the HealthXL Community

Commentary
HealthXL Team & HealthXL Community

A Round-up of 5 Expert Insights from the HealthXL Community

This past month, 138 of our HealthXL community members met across 14 meetings to discuss companion DTx in oncology, commercialization models for RPM, and evidence requirements for DTx reimbursement, among other topics. We’ve put together a snapshot of 5 expert insights from these meetings.


Expert Insights


#1 On DTx in Oncology: There are huge gaps in the cancer patient journey that can be addressed by DTx products (e.g. side effects management, comorbidities, etc.). However, one of the challenges to developing solutions in this space is the variation in drugs, treatments, comorbidities and patient needs. Building a solution that covers all needs in oncology can be very difficult. In this case niche solutions may be more successful for this TA. 


#2 On commercialization models for RPM: Hospital and Payer partnerships stood out as the most scalable and sustainable commercialization strategies for RPM. However, partnerships with other digital health companies will be uniquely positioned to give clinicians a full picture of their patients. Other important factors for success will be the solution’s integration with teleconsultation services, patient support programs and the existence of reimbursement codes.

#3 On Evidence for Reimbursement: RCTs might not be necessary to get reimbursed, but they really help. In Germany, you are not required to show RCT results to be listed in the DiGA directory, nevertheless, most companies are using RCTs as these are the industry gold standard for showing efficacy and safety. However, having clinical evidence may not be enough for payers. Economic evidence will be needed to get buy-in to the cost-reduction potential of a solution. In many cases, this data will need to be demonstrated time and time again rather than in a one-time study. 


#4 On defining populations for RCTs: It is important to have a representative population in your RCT in order to meet different users' needs/requirements. If the cohort studied is not diverse enough, health plans may not see the value of the solution if their generalized population is not represented in the results. Decentralized Clinical Trials are anticipated to be a valuable tool for increasing diversity and inclusion in clinical trials where barriers have previously existed.  


#5: On DH for Depression & Anxiety: There are a number of solutions in the mental health space, therefore for solutions that address depression and anxiety, product terminology and clarity is critical. PDT solutions for major depressive disorder (MDD) generalized anxiety disorder (GAD) are FDA cleared products and have high evidence requirements that are compared to the current standard of care. However, we are only starting to see RCTs for these products. These have not been extensively completed yet as they require larger sample sizes and are labeled as higher risk, making the expense of these trials often too high for small start-ups. 


Want to join the conversation? Check out our website for upcoming meetings and events. 

Interested in more expert insights and takeaways? Become a member of our HealthXL Community for access to polls and summaries from all of our meetings. 


We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

No upcoming Virtual Events scheduled. Please check back again soon.

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

16TH APRIL 2024 @ 11AM ET

Big Tech and Pharma: Will they, won't they?

As Big Tech seeks to expand their footprint in the health industry, the dynamics of their relationship with Pharma are under scrutiny.

Sophie Ghazal
Featuring
Sophie Ghazal
Global Digital Solutions and Strategic Alliances, Merck
18th April 2024 @ 11am ET

BYOD: What's your Wearable of Choice?

Wearables, like smartwatches and fitness trackers, have transformed patient health monitoring, providing real-time data for personalised care.

Ralph Morales III
Featuring
Ralph Morales III
Director, Healthcare Innovation, Oura
23RD APRIL 2024 @ 11AM ET

Masterclass: Digital Health Regulatory Updates

The digital health industry is revolutionising healthcare delivery, but navigating the ever-changing regulatory landscape can be daunting.

Piotr Sokolowski
Featuring
Piotr Sokolowski
Head of Strategy, MedTech Solutions at S3 Connected Health

HealthXL Insider Boston

Join HealthXL on the 23rd of April in Boston as we discuss the History of Digital Health: Learning from our Mistakes to Succeed in 2024.
Featuring

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.